EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access

Meropenem pharmacokinetics in cerebrospinal fluid: comparing intermittent and continuous infusion strategies in critically ill patients—a prospective cohort study

Sebastian G Wicha, Christina Kinast, Max Münchow, Sandra Wittova, Sebastian Greppmair, Alexandra K Kunzelmann, Michael Zoller, Michael Paal, Michael Vogeser, Katharina Habler, Thomas Weig, Nicole Terpolilli und 4 weitere

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00451-24 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Sebastian G Wicha und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Hamburg, Germany. Hauptthemen laut MEDLINE: Meropenem, Critical Illness, Anti-Bacterial Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: University of Munich LMU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Meropenem penetration into the cerebrospinal fluid (CSF) is subject to high interindividual variability resulting in uncertain target attainment in CSF. Recently, several authors recommended administering meropenem as a continuous infusion (CI) to optimize CSF exposure. This study aimed to compare the concentrations and pharmacokinetics of meropenem in CSF after intermittent infusion (II) and CI. This prospective, observational study (NCT04426383) included critically ill patients with external ventricular drains who received either II or CI of meropenem. Meropenem pharmacokinetics in plasma and CSF were characterized using population pharmacokinetic modeling (NONMEM 7.5). The developed model was used to compare the concentration–time profile and probability of target attainment (PTA) between II and CI. A total of 16 patients (8 CI, 8 II; samples: n plasma = 243, n CSF = 263) were recruited, with nine patients (5 CI, 4 II) suffering from cerebral and seven patients from extracerebral infections. A one-compartment model described the plasma concentrations adequately. Meropenem penetration into the CSF (partition coefficient (KP), c CSF /c plasma ) was generally low (6.0%), exhibiting substantial between-subject variability (coefficient of variation: 84.0%). There was no correlation between the infusion mode and KP, but interleukin (IL)-6 measured in CSF showed a strong positive correlation with KP ( P < 0.001). Dosing simulations revealed no relevant differences in CSF concentrations and PTA in CSF between CI and II. Our study did not demonstrate increased penetration rates or higher concentrations of meropenem in the CSF with CI compared with II. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT04426383 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeropenemCritical IllnessAnti-Bacterial AgentsHumansProspective StudiesMaleFemaleMiddle AgedAgedAdultInfusions, Intravenous

Stichwörter der Autor:innen

central nervous system infectionexternal ventricular drainmeningitispopulation pharmacokineticssepsisventriculitis

Substanzen

MeropenemAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Hamburg, Germany.
  • Department of Anaesthesiology, LMU University Hospital, LMU Munich, Munich, Germany.
  • Institute of Laboratory Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
  • Department of Neurosurgery, LMU University Hospital, LMU Munich, Munich, Germany.
  • Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany.

ORCID-Profile: Uwe Liebchen

Förderung

  • University of Munich LMU

Zitieren

APA

Wicha, S. G., Kinast, C., Münchow, M., Wittova, S., Greppmair, S., Kunzelmann, A. K., Zoller, M., Paal, M., Vogeser, M., Habler, K., Weig, T., Terpolilli, N., Heck, S., Dimitriadis, K., Scharf, C., & Liebchen, U. (2024). Meropenem pharmacokinetics in cerebrospinal fluid: comparing intermittent and continuous infusion strategies in critically ill patients—a prospective cohort study. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00451-24

Vancouver

Wicha SG, Kinast C, Münchow M, Wittova S, Greppmair S, Kunzelmann AK, et al. Meropenem pharmacokinetics in cerebrospinal fluid: comparing intermittent and continuous infusion strategies in critically ill patients—a prospective cohort study. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00451-24

BibTeX
@article{Wicha2024,
  author = {Wicha, Sebastian G and Kinast, Christina and Münchow, Max and Wittova, Sandra and Greppmair, Sebastian and Kunzelmann, Alexandra K and Zoller, Michael and Paal, Michael and Vogeser, Michael and Habler, Katharina and Weig, Thomas and Terpolilli, Nicole and Heck, Suzette and Dimitriadis, Konstantinos and Scharf, Christina and Liebchen, Uwe},
  title = {Meropenem pharmacokinetics in cerebrospinal fluid: comparing intermittent and continuous infusion strategies in critically ill patients—a prospective cohort study},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00451-24}
}
Kostenlos starten →